1.40
Telomir Pharmaceuticals Inc stock is traded at $1.40, with a volume of 148.11K.
It is up +0.39% in the last 24 hours and down -10.48% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$1.40
Open:
$1.4
24h Volume:
148.11K
Relative Volume:
0.05
Market Cap:
$48.13M
Revenue:
-
Net Income/Loss:
$-16.14M
P/E Ratio:
-2.5926
EPS:
-0.54
Net Cash Flow:
$-3.99M
1W Performance:
-1.02%
1M Performance:
-10.48%
6M Performance:
-43.78%
1Y Performance:
-57.54%
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TELO
Telomir Pharmaceuticals Inc
|
1.40 | 48.13M | 0 | -16.14M | -3.99M | -0.54 |
|
ARGX
Argen X Se Adr
|
918.87 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.47 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
202.51 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
364.63 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.82 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Does Telomir Pharmaceuticals Inc. stock trade at a discount to peersMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com
Analyzing Telomir Pharmaceuticals Inc. with risk reward ratio chartsLong Setup & Detailed Earnings Play Alerts - newser.com
Will Telomir Pharmaceuticals Inc. bounce back from current supportGap Down & Low Risk Growth Stock Ideas - newser.com
What’s the recovery path for long term holders of Telomir Pharmaceuticals Inc.Sell Signal & High Win Rate Trade Tips - newser.com
Will Telomir Pharmaceuticals Inc. rebound enough to break even2025 Retail Activity & Reliable Trade Execution Plans - newser.com
Has Telomir Pharmaceuticals Inc. found a price floor2025 Analyst Calls & Low Risk High Reward Ideas - newser.com
What Institutional Trends Suggest About Harshdeep Hortico Limiteds DirectionStock Watchlist Updates & Explosive Capital Growth - earlytimes.in
Is Telomir Pharmaceuticals Inc a good long term investmentCandlestick Pattern Analysis & Budget Friendly Portfolio - earlytimes.in
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How Telomir Pharmaceuticals Inc. stock reacts to global recession fearsMarket Activity Recap & Free Fast Gain Swing Trade Alerts - newser.com
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line - The Florida Times-Union
Sentiment analysis tools applied to Telomir Pharmaceuticals Inc.2025 Dividend Review & Reliable Breakout Stock Forecasts - newser.com
Momentum divergence signals in Telomir Pharmaceuticals Inc. chartJuly 2025 PostEarnings & Weekly Top Gainers Trade List - newser.com
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Re - The Marion Star
Telomir Pharmaceuticals (NASDAQ: TELO): Telomir-1 beats DFO in live-cell iron reduction - Stock Titan
Telomir Pharmaceuticals Unveils Promising Preclinical Data - TipRanks
Telomir Pharmaceuticals enters into stock purchase agreement - MSN
Forecasting Telomir Pharmaceuticals Inc. price range with options dataRate Hike & Weekly Setup with ROI Potential - newser.com
What technical models suggest about Telomir Pharmaceuticals Inc.’s comebackJuly 2025 Rallies & Comprehensive Market Scan Reports - newser.com
What insider trading reveals about Telomir Pharmaceuticals Inc. stockEarnings Growth Report & Expert-Curated Trade Recommendations - newser.com
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):